Radiotherapy in thymic neoplasms

Tony Y. Eng, Aidnag Z. Diaz, Join Y. Luh

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The role of adjuvant radiotherapy in thymic tumors has not been explicitly defined. Since epithelial thymic tumors are relatively radiosensitive, many clinicians advocate the use of adjuvant radiation therapy in all cases, in addition to those cases where there is extension beyond the capsule [1]-[4]. Justification for adjuvant radiation is based on studies showing decreased recurrence rates for stage II disease with adjuvant therapy from 30% to 5% [5, 6]. Other groups suggest that, due to the low incidence of local recurrence after complete resection of stage II thymomas, radiation therapy should be reserved for selected patients [7]-[10]. Schmidt-Wolf [11] proposed that adjuvant external-beam radiotherapy should be considered only for stages II and III disease where there were extensive adhesions between tumor and pleura, microscopic pleural infiltration, or macroscopic invasion of the pericardium, large vessels, or lung. In addition, Chen [12] noted that completely resected stage II thymomas of WHO subtype A, AB, and B-I may not require adjuvant therapy.

Original languageEnglish (US)
Title of host publicationThymus Gland Pathology
Subtitle of host publicationClinical, Diagnostic, and Therapeutic Features
PublisherSpringer Milan
Pages229-239
Number of pages11
ISBN (Print)9788847008274
DOIs
StatePublished - Dec 1 2008

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Radiotherapy in thymic neoplasms'. Together they form a unique fingerprint.

Cite this